Zentalis Pharmaceuticals, Inc. beat EPS estimates 0% of the time across 3 reported quarters (0 beats, 3 misses), averaging -17.6% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.45 | $-0.59 | -31.1% | Miss | |
| Q1 FY26 | $-0.49 | $-0.50 | -2.0% | Miss | |
| Q4 FY25 | $-0.41 | $-0.49 | -19.5% | Miss |
Back to ZNTL overview · ZNTL holders · ZNTL KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.